(Reuters) - Abbott Laboratories
Despite the earnings beat, Abbott left its full-year profit forecast unchanged at $1.98 to $2.04 per share.
The company, which in January spun off its branded prescription drugs business into a new company called AbbVie Inc
Excluding special items, it earned 46 cents per share. Analysts, on average, expected 44 cents, according to Thomson Reuters I/B/E/S.
Revenue rose 2.5 percent to $5.45 billion, slightly below Wall Street expectations for $5.52 billion.
(Reporting by Ransdell Pierson; Editing by John Wallace)
(c) Copyright Thomson Reuters 2013. Check for restrictions at: http://about.reuters.com/fulllegal.asp